[HLBANK] QoQ Quarter Result on 30-Sep-2021 [#1]

Stock
[HLBANK] HONG LEONG BANK BHD
Announcement Date
29-Nov-2021
Admission Sponsor
-
Sponsor
-
Financial Year
30-Jun-2022
Quarter
30-Sep-2021 [#1]
Profit Trend
QoQ- 24.48%
YoY- 17.75%
Quarter Report
Latest QR
Upcoming QR
HLBANK's Result
HLBANK's Financial Summary
View:
Show?
Quarter Result
30/06/22 31/03/22 31/12/21 30/09/21 30/06/21 31/03/21 31/12/20 CAGR
Revenue 1,498,395 1,347,904 1,371,167 1,379,942 1,332,291 1,385,643 1,400,088 4.64%
PBT 1,217,328 1,030,823 1,076,537 1,042,112 824,611 940,789 815,290 30.73%
Tax -309,688 -246,025 -337,944 -183,860 -135,127 -169,323 -144,502 66.45%
NP 907,640 784,798 738,593 858,252 689,484 771,466 670,788 22.40%
-
NP to SH 907,640 784,798 738,593 858,252 689,484 771,466 670,788 22.40%
-
Tax Rate 25.44% 23.87% 31.39% 17.64% 16.39% 18.00% 17.72% -
Total Cost 590,755 563,106 632,574 521,690 642,807 614,177 729,300 -13.13%
-
Net Worth 31,006,211 30,351,463 30,062,673 29,448,800 29,461,726 28,539,430 28,251,912 6.41%
Dividend
30/06/22 31/03/22 31/12/21 30/09/21 30/06/21 31/03/21 31/12/20 CAGR
Div 758,248 - 368,615 - 721,085 - 302,582 84.80%
Div Payout % 83.54% - 49.91% - 104.58% - 45.11% -
Equity
30/06/22 31/03/22 31/12/21 30/09/21 30/06/21 31/03/21 31/12/20 CAGR
Net Worth 31,006,211 30,351,463 30,062,673 29,448,800 29,461,726 28,539,430 28,251,912 6.41%
NOSH 2,167,718 2,167,718 2,167,718 2,167,718 2,167,718 2,167,718 2,167,718 0.00%
Ratio Analysis
30/06/22 31/03/22 31/12/21 30/09/21 30/06/21 31/03/21 31/12/20 CAGR
NP Margin 60.57% 58.22% 53.87% 62.19% 51.75% 55.68% 47.91% -
ROE 2.93% 2.59% 2.46% 2.91% 2.34% 2.70% 2.37% -
Per Share
30/06/22 31/03/22 31/12/21 30/09/21 30/06/21 31/03/21 31/12/20 CAGR
RPS 73.12 65.82 66.96 67.34 65.07 67.68 68.39 4.57%
EPS 44.32 38.32 36.07 41.91 33.68 37.68 32.77 22.36%
DPS 37.00 0.00 18.00 0.00 35.22 0.00 14.78 84.67%
NAPS 15.13 14.82 14.68 14.37 14.39 13.94 13.80 6.34%
Adjusted Per Share Value based on latest NOSH - 2,167,718
30/06/22 31/03/22 31/12/21 30/09/21 30/06/21 31/03/21 31/12/20 CAGR
RPS 73.09 65.75 66.89 67.32 64.99 67.59 68.30 4.63%
EPS 44.28 38.28 36.03 41.87 33.63 37.63 32.72 22.41%
DPS 36.99 0.00 17.98 0.00 35.18 0.00 14.76 84.81%
NAPS 15.1254 14.806 14.6651 14.3657 14.372 13.9221 13.7818 6.41%
Price Multiplier on Financial Quarter End Date
30/06/22 31/03/22 31/12/21 30/09/21 30/06/21 31/03/21 31/12/20 CAGR
Date 30/06/22 31/03/22 31/12/21 30/09/21 30/06/21 31/03/21 31/12/20 -
Price 20.46 20.20 18.62 18.90 18.72 18.70 18.20 -
P/RPS 27.98 30.69 27.81 28.07 28.77 27.63 26.61 3.41%
P/EPS 46.20 52.71 51.63 45.13 55.59 49.63 55.55 -11.59%
EY 2.16 1.90 1.94 2.22 1.80 2.02 1.80 12.96%
DY 1.81 0.00 0.97 0.00 1.88 0.00 0.81 71.17%
P/NAPS 1.35 1.36 1.27 1.32 1.30 1.34 1.32 1.51%
Price Multiplier on Announcement Date
30/06/22 31/03/22 31/12/21 30/09/21 30/06/21 31/03/21 31/12/20 CAGR
Date 30/08/22 30/05/22 28/02/22 29/11/21 30/08/21 27/05/21 26/02/21 -
Price 20.92 21.12 20.08 18.16 19.20 17.90 18.00 -
P/RPS 28.61 32.09 29.99 26.97 29.51 26.45 26.32 5.73%
P/EPS 47.23 55.11 55.67 43.36 57.01 47.50 54.94 -9.61%
EY 2.12 1.81 1.80 2.31 1.75 2.11 1.82 10.73%
DY 1.77 0.00 0.90 0.00 1.83 0.00 0.82 67.25%
P/NAPS 1.38 1.43 1.37 1.26 1.33 1.28 1.30 4.07%

PBT = Profit before Tax, NP = Net Profit, NP to SH = Net Profit Attributable to Shareholder, Div = Dividend, NP Margin = Net Profit Margin, ROE = Return on Equity, NOSH = Number of Shares, RPS = Revenue per Share, EPS = Earning Per Share, DPS = Dividend Per Share, NAPS = Net Asset Per Share, EOQ = End of Quarter, ANN = Announcement, P/RPS = Price/Revenue per Share, P/EPS = Price/Earning per Share, P/NAPS = Price/Net Asset per Share, EY = Earning Yield, DY = Dividend Yield.

NOSH is estimated based on the NP to SH and EPS. Div is an estimated figure based on the DPS and NOSH. Net Worth is an estimated figure based on the NAPS and NOSH.

Div Payout %, NP Margin, ROE, DY, QoQ ⃤ & YoY ⃤ figures in Percentage; RPS, EPS & DPS's figures in Cent; and NAPS's figures in Dollar.

All figures in '000 unless specified.

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment